Table 2. All AEs resulting from anlotinib treatment in patients with HCC (N=27).

AEs	n (%)
	Any grade	Grade 3
AE, adverse event; HCC, hepatocellular carcinoma.
Hypertension	6 (22.2)	2 (7.4)
Platelet count decreased	6 (22.2)	0 (0)
Hand-foot syndrome	4 (14.8)	1 (3.7)
Sphagitis	3 (11.1)	0 (0)
Fever	1 (3.7)	0 (0)
Abdominal distension	1 (3.7)	0 (0)
Diarrhea	1 (3.7)	0 (0)
Vomiting	1 (3.7)	0 (0)